Want to see HK:1345 full AI Analyst Report?
Top Page
Shanghai Pioneer Holding Ltd
(1345)
Select Model
Select Model
Rating:67Neutral
Price Target:
HK$2.50
▲(11.61% Upside)
Action:Reiterated
Date:08/17/26
Overall score reflects a strong financial foundation (low leverage) and improved recent free cash flow, which are the primary supports. The score is tempered by weakening fundamentals (TTM revenue decline and lower margins/returns versus 2022) and only modest technical strength (below key moving averages with slightly negative MACD). Valuation is fair with an attractive dividend yield, but not enough to fully offset the growth and momentum concerns.
Positive Factors
Conservative balance sheet
Low leverage and a substantial equity base reduce financial strain and preserve flexibility for investment or resilience. This conservative funding structure is a durable support even while operating performance is uneven.
Negative Factors
Declining revenue trend
The latest revenue contraction signals weaker demand or market execution in the core business. A sustained top-line decline can reduce operating leverage, constrain reinvestment and make recovery in earnings more dependent on cost control.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
Low leverage and a substantial equity base reduce financial strain and preserve flexibility for investment or resilience. This conservative funding structure is a durable support even while operating performance is uneven.
Read all positive factors
Shanghai Pioneer Holding Ltd (1345) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$2.64B
Dividend Yield5.45%
Average Volume (3M)50.13K
Price to Earnings (P/E)17.6
Beta (1Y)0.19
Revenue Growth-5.80%
EPS Growth22.06%
CountryHK
Employees448
SectorHealthcare
Sector Strength45
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)0.11
Shares Outstanding1,257,447,000
10 Day Avg. Volume20,600
30 Day Avg. Volume50,133
Financial Highlights & Ratios
PEG Ratio-0.90
Price to Book (P/B)2.33
Price to Sales (P/S)1.90
P/FCF Ratio12.95
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Shanghai Pioneer Holding Ltd Business Overview & Revenue Model
Company Description
China Pioneer Pharma Holdings Limited operates as an investment holding company, primarily focusing on the marketing, promotion, and distribution of pharmaceutical goods and medical devices within mainland China. The firm maintains an extensive po...
How the Company Makes Money
null...
Shanghai Pioneer Holding Ltd Financial Statement Overview
Summary
Income Statement
62
Positive
Balance Sheet
82
Very Positive
Cash Flow
74
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.24B | 1.28B | 1.53B | 1.57B | 1.56B | 1.43B |
| Gross Profit | 641.49M | 627.14M | 683.21M | 668.24M | 780.47M | 772.03M |
| EBITDA | 164.70M | 172.38M | 215.27M | 201.88M | 245.38M | 199.96M |
| Net Income | 123.05M | 114.38M | 151.62M | 145.72M | 235.30M | 142.63M |
Balance Sheet | ||||||
| Total Assets | 1.61B | 1.49B | 1.46B | 1.53B | 1.57B | 1.33B |
| Cash, Cash Equivalents and Short-Term Investments | 159.15M | 210.74M | 103.57M | 124.43M | 289.01M | 402.08M |
| Total Debt | 218.01M | 121.44M | 75.22M | 74.02M | 37.59M | 14.05M |
| Total Liabilities | 573.32M | 444.47M | 342.52M | 513.14M | 549.18M | 417.49M |
| Stockholders Equity | 1.04B | 1.05B | 1.11B | 1.01B | 1.01B | 907.97M |
Cash Flow | ||||||
| Free Cash Flow | 137.44M | 188.74M | 208.01M | -163.24M | 19.02M | 225.43M |
| Operating Cash Flow | 146.92M | 215.27M | 214.83M | -118.69M | 93.30M | 242.06M |
| Investing Cash Flow | -70.31M | -75.62M | -99.76M | 69.51M | -12.99M | 8.39M |
| Financing Cash Flow | -64.92M | -61.11M | -125.92M | -50.56M | -91.03M | -140.28M |
Shanghai Pioneer Holding Ltd Technical Analysis
Negative
2.24
Price Trends
2.24
Negative
2.23
Negative
2.20
Negative
Market Momentum
>-0.01
Negative
47.77
Neutral
55.56
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1345, the sentiment is Negative. The current price of 2.24 is above the 20-day moving average (MA) of 2.21, above the 50-day MA of 2.24, and above the 200-day MA of 2.20, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 47.77 is Neutral, neither overbought nor oversold. The STOCH value of 55.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1345.
Shanghai Pioneer Holding Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | HK$4.24B | 16.10 | 10.01% | 5.16% | -4.20% | -25.69% | |
67 Neutral | HK$2.64B | 17.58 | 11.78% | 5.45% | -5.80% | 22.06% | |
62 Neutral | HK$1.92B | 13.53 | 8.16% | ― | 20.65% | 127.07% | |
62 Neutral | HK$2.92B | -37.01 | -5.91% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | HK$3.43B | -20.49 | -7.65% | ― | 21.23% | 36.89% | |
43 Neutral | HK$1.63B | -0.86 | -6.69% | ― | ― | ― |
* Healthcare Sector Average
HK:1345
Shanghai Pioneer Holding Ltd
2.20
0.52
31.19%
HK:9996
Peijia Medical Ltd.
5.06
-2.65
-34.37%
HK:6669
Acotec Scientific Holdings Limited
6.01
-8.62
-58.92%
HK:2160
MicroPort CardioFlow Medtech Corp.
1.28
-6.07
-82.59%
HK:2291
LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. Class H
11.10
-10.02
-47.44%
HK:2576
Zhejiang Taimei Medical Technology Co Ltd Class H
5.00
0.35
7.53%
Shanghai Pioneer Holding Ltd Corporate Events
Shanghai Pioneer Board to Review Interim Results and Consider Dividend
Aug 18, 2026
Shanghai Pioneer Holding Ltd has announced that its board of directors will convene on 28 August 2026 to review and approve the company’s interim results for the six months ended 30 June 2026. The meeting will also consider the publication o...
Shanghai Pioneer Holding Shareholders Approve All AGM Resolutions and Final Dividend
May 22, 2026
Shareholders of Shanghai Pioneer Holding Ltd approved all resolutions at the annual general meeting held on 22 May 2026, with voting conducted by poll and supervised by the Hong Kong branch share registrar. Major shareholders connected to Mr. Li X...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.